These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
411 related articles for article (PubMed ID: 18180459)
1. Signaling networks assembled by oncogenic EGFR and c-Met. Guo A; Villén J; Kornhauser J; Lee KA; Stokes MP; Rikova K; Possemato A; Nardone J; Innocenti G; Wetzel R; Wang Y; MacNeill J; Mitchell J; Gygi SP; Rush J; Polakiewicz RD; Comb MJ Proc Natl Acad Sci U S A; 2008 Jan; 105(2):692-7. PubMed ID: 18180459 [TBL] [Abstract][Full Text] [Related]
2. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490 [TBL] [Abstract][Full Text] [Related]
3. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904 [TBL] [Abstract][Full Text] [Related]
4. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET. Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446 [TBL] [Abstract][Full Text] [Related]
5. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990 [TBL] [Abstract][Full Text] [Related]
9. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines. Kani K; Garri C; Tiemann K; Malihi PD; Punj V; Nguyen AL; Lee J; Hughes LD; Alvarez RM; Wood DM; Joo AY; Katz JE; Agus DB; Mallick P Mol Cancer Ther; 2017 Aug; 16(8):1645-1657. PubMed ID: 28566434 [TBL] [Abstract][Full Text] [Related]
10. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767 [TBL] [Abstract][Full Text] [Related]
11. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer. Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272 [TBL] [Abstract][Full Text] [Related]
12. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
13. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395 [TBL] [Abstract][Full Text] [Related]
14. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway. Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070 [TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805 [TBL] [Abstract][Full Text] [Related]
16. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075 [TBL] [Abstract][Full Text] [Related]
17. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer. Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032 [TBL] [Abstract][Full Text] [Related]
18. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074 [TBL] [Abstract][Full Text] [Related]
19. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells. Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520 [TBL] [Abstract][Full Text] [Related]
20. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]